Philadelphia – November 03, 2026 -- Verismo Therapeutics' SynKIR-110 achieved the fastest tumor control among three CAR T designs in preclinical mesothelioma models while producing roughly 10-fold less IFNγ and 30-fold less TNFα and IL-2 than a CD28-based single-chain CAR T.

The company will present the data at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix (Abstract 253). The study compared SynKIR-110 with CD28- and 4-1BB-based single-chain CAR T cells in mesothelioma xenograft models.

Cambridge, Mass. – October 02, 2026 -- Marengo Therapeutics will present interim results from its STARt-002 trial combining invikafusp alfa with Gilead's TRODELVY (sacituzumab govitecan-hziy) at the Society for Immunotherapy of Cancer's 41st Annual Meeting in Phoenix, Arizona, November 4-8, 2026.